Ziextenzo 6,0 mg Solution for injection
PDF Leaflet Revision Date: 25 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce duration and incidence of neutropenia in chemotherapy patients.
Dosage (summary)
6 mg subcutaneously, 24 hours post-chemotherapy cycle.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; insufficient data for breastfeeding.
Key Drug Interactions
- Cytotoxic chemotherapy
- Lithium
- 5-fluorouracil
Contraindications
- Hypersensitivity to pegfilgrastim or excipients
Common side effects
- Bone pain
- Musculoskeletal pain
- Nausea
- Headache
Counselling Points
- Monitor for allergic reactions
- Report any pulmonary symptoms
- Avoid in hypersensitivity history
Serious warnings
- Pulmonary adverse events
- Capillary leak syndrome
- Splenic rupture
- Myelodysplastic syndrome
Important Disclaimer
The Ziextenzo 6,0 mg Solution for injection professional information leaflet below is the property of Sandoz Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
